PGXIS PGXIS is a genomics company with a range of technologies designed to increase the efficiency of drug discovery and development. We have expertise in clinical pharmacogenomics and a novel analysis method (Tax3) which generates rich insights into diseases and drug adverse events. Through our parent company, CytoPathfinder Inc., we also have access to leading in vitro siRNA methodology. Using these technologies we work with our customers to enhance their drug discovery and development programmes.